Disease relevance of Second-Look Surgery

• CEA-directed second-look surgery in the asymptomatic patient after primary resection of colorectal carcinoma [1].
• OBJECTIVE: To prospectively evaluate the ability for immunoscintigraphy with monoclonal antibody CYT-103 labeled with indium 111 to detect tumor presence in 15 patients with ovarian cancer undergoing second-look surgery [2].
• Twenty-seven patients with frankly invasive nonmucinous invasive adenocarcinoma of the ovary were monitored using a serial CA-125 and lipid-associated sialic acid (LASA-P) levels prior to cytoreductive surgery, during chemotherapy, before second-look surgery or disease progression, and during subsequent follow-up [3].
• A local recurrence correlating with a slow CEA rise was generally resectable, metastases correlating with a rapid CEA rise were only in some cases resectable, provided that second-look surgery was carried out without delay [4].

High impact information on Second-Look Surgery

• Eight had no clinical evidence of recurrent cancer and they might have had negative second-look surgery had this been done because of CEA rises alone [5].
• PATIENTS AND METHODS: Forty-four eligible POG stage C infants received cyclophosphamide 150 mg/m2 orally on days 1 to 7 and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) 35 mg/m2 intravenously (IV) on day 8 (CYC/ADR), every 3 weeks for five courses followed by second-look surgery [6].
• Two of the latter cases had single copy of N-myc in a second-look surgery sample, but no tumor was evident histologically [7].
• All except seven patients were maintained on parenteral nutrition before second-look surgery for jejunostomy closure [8].
• Amifostine pretreatment did not affect the antitumor effects of CP as assessed by response determined at second-look surgery or overall survival [9].

Chemical compound and disease context of Second-Look Surgery

• Trends in CA-125 levels after completion of therapy in ovarian cancer patients who received intraperitoneal radioactive chromic phosphate therapy (32P) after primary surgical resection or second-look surgery were evaluated [10].
• The value of IP mitoxantrone was studied as consolidation treatment of ovarian cancer in pCR at second-look surgery [11].

Anatomical context of Second-Look Surgery

• The need for second-look surgery after chemotherapy in children with advanced germ cell tumors is controversial, particularly when levels of the tumor markers alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta HCG) are elevated at diagnosis [12].

Associations of Second-Look Surgery with chemical compounds

• Two patients had positive second-look surgery, one with stage IIIC disease treated with a cisplatin combination and the other with stage IC disease treated with melphalan [13].
• In the hope of improving outcome, we have treated 17 women with sequential multimodality therapy, including initial surgical resection (if possible), cyclophosphamide-adriamycin +/- cis-platinum, second-look surgery, and whole abdominal irradiation [14].
• Among 8 patients treated with HMF and either intraperitoneal chromic phosphate and/or alternating platinum-based chemotherapy following second-look surgery which documented persistent carcinoma, 3 have experienced disease-free intervals of 19, 27, and 42 months [15].
• Second-look surgery was performed in 10 patients; six results were negative after melphalan therapy, one was negative after cisplatin combination therapy, and one was negative after no adjuvant treatment [13].
• OBJECTIVE: The aim of this study was to determine the feasibility and efficacy of intraperitoneal cisplatin and mitoxantrone in patients with very small-volume residual disease at second-look surgery after completion of primary platinum-based intravenous chemotherapy [16].

Gene context of Second-Look Surgery

• In patients with stage II-IV disease who underwent second-look surgery after primary chemotherapy, a significant correlation between high EGFR levels and poor response to chemotherapy was demonstrated (P = 0.031) [17].
• This review analyzes the relative values of the preoperative CEA and postoperative serial CEA levels, the correlation with different patterns of recurrence, and the potential for detecting early recurrence and selecting patients for second-look surgery [18].
• This correlation disappeared before second-look surgery because 60% of patients with normal serum CA 125 and N-acetylglucosamine:beta1,4-galactosyltransferase levels [19].
• Only 7 of 18 patients (39%) with gross residual disease at second-look surgery had an elevated CA 125 level [20].
• Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, Ca 19-9 analysis and second-look surgery [21].

Analytical, diagnostic and therapeutic context of Second-Look Surgery

• Crude and disease-free survival rates were similar in both groups randomized at second-look surgery to receive either phosphorus-32 or no treatment [22].

References